Search clinical trials for: Sunitinib (SU011248)

Total 490 results

University Health Network, Toronto
Pfizer

Completed

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma (SNIPP)

Pheochromocytoma | Paraganglioma

Canada, Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Exelixis

Active, not recruiting

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Malignant Neoplasms of Urinary Tract | Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3... and other conditions

United States
Case Comprehensive Cancer Center

Completed

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

Uterine Carcinosarcoma | Recurrent Uterine Corpus Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Stage IVA Uterine Corpus Cancer AJCC v7 | Stage IVB Uterine Corpus Cancer AJCC v7 | Uterine Corpus Carcinosarcoma

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma

United States, Korea, Republic of
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Recurrent Childhood Ependymoma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Subependymal Giant Cell Astrocytoma | Childhood Mixed Glioma | Childhood Oligodendroglioma and other conditions

United States, Canada, Australia
AGO Study Group
Philipps University Marburg Medical Center; HSK Reasearch GmbH Wiesbaden

Completed

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

Platinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian Tube

Germany
National Cancer Institute (NCI)

Active, not recruiting

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Recurrent Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage... and other conditions

United States
Pfizer

Completed

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

Neoplasms | Breast Cancer | Solid Tumors

United States
National Cancer Institute (NCI)

Completed

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Case Comprehensive Cancer Center
Pfizer

Terminated

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Recurrent Bladder Cancer | Transitional Cell Carcinoma of the Bladder

United States
Dwight Owen
National Cancer Institute (NCI)

Suspended

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Thymic Carcinoma

United States
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
Pfizer

Completed

An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer

Liver Neoplasms | Unresectable Hepatocellular Carcinoma

Korea, Republic of, Taiwan, France
National Cancer Institute (NCI)

Completed

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma

Leiomyosarcoma | Fibrosarcoma | Liposarcoma | Malignant Fibrous Histiocytoma

United States
Tony Bekaii-Saab
Pfizer

Completed

Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer

Esophageal Cancer

United States
Pfizer

Completed

A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors

Solid Tumors

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Pfizer

Active, not recruiting

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage IIIC Intraocular Melanoma | Stage I Intraocular Melanoma | Stage IIA Intraocular Melanoma | Stage IIB Intraocular... and other conditions

United States
Duke University
Pfizer

Completed

Ph I SU011248 + Irinotecan in Treatment of Pts w MG

Glioblastoma

United States
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group...

Completed

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery (ASSURE)

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer AJCC v7 | Stage I Renal Cell Cancer AJCC v6 and v7

United States, Canada, Puerto Rico
Pfizer

Completed

Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (MRCC RCC)

Carcinoma, Renal Cell

China
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
Pfizer

Terminated

Sunitinib Malate in Refractory Germ Cell Tumors

Genitourinary Disease

United States
Pfizer

Completed

A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.

Carcinoma, Renal Cell

United States
Pfizer

Completed

Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer

Carcinoma, Renal Cell Metastasis

France, Sweden, United States, Germany, Switzerland, Netherlands, Greece
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

Canada, United States
Pfizer

Completed

Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

China
Pfizer

Completed

A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

Japan
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma

Canada
Swedish Medical Center
Pfizer

Completed

Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

Adenocarcinoma | Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Cervical Adenosquamous Cell Carcinoma

Canada
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIB Fallopian Tube Cancer | Stage IIIC Fallopian Tube Cancer and other conditions

Canada
Pfizer

Completed

A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

Neoplasms

United States, Canada, France, Germany, Italy, United Kingdom, Spain
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus

Recurrent Uterine Sarcoma | Uterine Leiomyosarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Completed

A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma

Glioblastoma | Anaplastic Astrocytoma

United States
Alberta Health services
Pfizer

Unknown

Sutent Maintenance After Response to Taxotere (SMART)

Prostate Cancer | Hormone Refractory

Canada
British Columbia Cancer Agency
Canadian Urologic Oncology Group; German Testicular Cancer Study Group; NCIC...

Completed

Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer

Relapsed or Cisplatin-Refractory Germ Cell Cancer

Canada
University of Washington
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Relapsed or Refractory Diffuse or Mediastinal Large B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Adult Diffuse Large Cell Lymphoma

Canada
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine

Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
M.D. Anderson Cancer Center
Pfizer

Completed

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

Kidney Cancer | Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Adult Anaplastic Astrocytoma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pineal Gland Astrocytoma

United States
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)

Withdrawn

Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Classic Kaposi Sarcoma | AIDS-related Kaposi Sarcoma
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
AHS Cancer Control Alberta
Pfizer

Completed

SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial (SPRUCE)

Bladder Cancer | Urothelial Cancer | Adult

Canada
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Terminated

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

Liver Cancer

United States

Search clinical trials for: Sunitinib (SU011248)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations